Acadia Pharmaceuticals (ACAD) said late Tuesday it has struck a deal to sell its rare pediatric disease priority review voucher for $150 million.
Acadia said it was granted the voucher in March 2023 following approval from the US Food and Drug Administration of DAYBUE to treat Rett syndrome.
Acadia initially licensed DAYBUE from Neuren Pharmaceuticals in August 2018, and is required to pay Neuren a third of the net proceeds.
The company said it plans to invest the proceeds in commercial operations, research and development programs in the central nervous system and rare diseases, and in future business development.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。